HC Wainwright Lowers Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at HC Wainwright reduced their Q4 2026 earnings estimates for shares of TG Therapeutics in a report released on Monday, July 13th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of $0.31 per share for the quarter, down from their previous forecast of $0.41. HC Wainwright has a “Buy” rating and a $77.00 price objective on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $1.51 per share. HC Wainwright also issued estimates for TG Therapeutics’ FY2027 earnings at $2.32 EPS.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.11). The company had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. TG Therapeutics’s revenue was up 69.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.03 EPS.

TGTX has been the subject of a number of other research reports. Bank of America lifted their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Finally, Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.33.

TG Therapeutics Price Performance

Shares of TGTX opened at $55.01 on Tuesday. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The company’s fifty day simple moving average is $46.60 and its 200 day simple moving average is $36.52. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $59.30. The company has a market cap of $8.42 billion, a price-to-earnings ratio of 19.23, a PEG ratio of 1.38 and a beta of 1.60.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently modified their holdings of the business. Danske Bank A S bought a new position in TG Therapeutics in the third quarter valued at about $25,000. EverSource Wealth Advisors LLC boosted its stake in shares of TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 365 shares in the last quarter. Hantz Financial Services Inc. boosted its stake in shares of TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC grew its holdings in shares of TG Therapeutics by 172.4% during the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in TG Therapeutics during the 4th quarter worth approximately $52,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.